AN-6005

N/A

Report date: 2025/01/26 17:13:05

Base Information

Drug NameAN-6005

Drug Alias NameAN-6005

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionT lymphocytes stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesHangzhou Adlai Nortye Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Adlai Nortye Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A